First US FDA RMAT Designation Of 2019 Goes To ExCellThera’s ECT-001

24 Apr 2019

Five-month drought broken by ExCellThera’s "optimized culture system" designation for treatment of hematologic malignancies. The Pink Sheet details each of the 27 announced Regenerative Medicine Advanced Therapy designations in a table.

Front door, black front door — Welcome to the next stage in your development, ECT-001.

First US FDA RMAT Designation Of 2019 Goes To ExCellThera’s ECT-001

More from Review Pathways

More from Pathways & Standards